Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation


Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish InitiationIn the next few years, Ulz said he anticipates "meaningful upside" stemming from early clinical data on antibodies that inhibit CD47, such as SRF231. The drug has broad utility and a differentiated safety profile, Ulz said. A Novartis AG (NYSE: NVS) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.